CyBio to be Merged into Analytik Jena
News Apr 11, 2014
Against this backdrop, CyBio AG will be merged into Analytik Jena AG during the current financial year. A corresponding merger by absorption agreement was signed this past Friday.
As part of the merger by absorption, Analytik Jena AG plans to acquire all the remaining shares of CyBio AG by means of a method to squeeze out minority shareholders (known as a squeeze-out merger). The shareholders of CyBio AG are to draft a resolution to transfer the shares of the minority shareholders to Analytik Jena AG as the majority shareholder in return for payment of compensation in cash at the Company's General Meeting on May 22, 2014. Analytik Jena AG currently holds 91.9% of the voting rights of CyBio AG.
The business activities of the CyBio Group are to be continued after the merger becomes effective and to be expanded in the coming years. CyBio products and services will continue to be marketed as an independent CyBio product line under the CyBio brand by Analytik Jena AG. CyBio AG currently employs 98 staff members around the world and is fully consolidated in the Analytik Jena Group. Analytik Jena AG already acquired the majority of the shares of CyBio AG in 2009.
"With the strategic and operational realignment of CyBio AG, we have consistently driven business in a customer-oriented way in the areas of liquid handling and laboratory automation technology in the past five years as part of the Analytik Jena Group. CyBio AG has become an integral and successful part of the Analytik Jena AG family," said Klaus Berka, Chief Executive Officer of Analytik Jena AG. "The planned merger and structural integration is the logical continuation of this path with the aim of bundling our competencies in the Group portfolio and thus providing access for our customers to an even more comprehensive range."
Bioethics Council Rules Heritable Genome Editing "Ethically Acceptable" In Certain CircumstancesNews
A leading UK bioethics advisory body has weighed in on the debate around human genetic modification, concluding that heritable genome editing – modifying the DNA of an egg, sperm or embryo with changes that will be passed on to future generations – could be ‘morally permissible’ in humans, provided key ethical tests are met.
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019